Research programme: antigen presenting cell-based therapeutics - NexImmune

Drug Profile

Research programme: antigen presenting cell-based therapeutics - NexImmune

Alternative Names: AIM 101; AIM 102; AIM 103; AIM 104; AIM ACT

Latest Information Update: 21 Jul 2015

Price : $50

At a glance

  • Originator NexImmune
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Autoimmune disorders; Infections

Most Recent Events

  • 21 Jul 2015 Antigen presenting cell-based therapeutics are covered by patent protection in USA (NexImmune website, July 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top